Compare · ADXN vs MRK
ADXN vs MRK
Side-by-side comparison of Addex Therapeutics Ltd (ADXN) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXN and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $385.99B, about 78186.2x ADXN ($4.9M).
- Over the past year, ADXN is down 39.1% and MRK is up 84.0% - MRK leads by 123.2 points.
- MRK has been more active in the news (17 items in the past 4 weeks vs 2 for ADXN).
- MRK has more recent analyst coverage (25 ratings vs 2 for ADXN).
- Company
- Addex Therapeutics Ltd
- Merck & Company Inc.
- Price
- $4.93-1.60%
- $156.44+3.81%
- Market cap
- $4.9M
- $385.99B
- 1M return
- -18.65%
- +19.67%
- 1Y return
- -39.14%
- +84.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 17
- Recent ratings
- 2
- 25
Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest ADXN
- SEC Form 6-K filed by Addex Therapeutics Ltd
- ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
- SEC Form 6-K filed by Addex Therapeutics Ltd
- Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
- SEC Form 6-K filed by Addex Therapeutics Ltd
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- SEC Form 6-K filed by Addex Therapeutics Ltd
- Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
- SEC Form 6-K filed by Addex Therapeutics Ltd
Latest MRK
- Merck downgraded by RBC Capital Mkts with a new price target
- Merck upgraded by Morgan Stanley with a new price target
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)